Aimmune Therapeutics (AIMT) PT Raised to $45 at JMP Securities
Tweet
Share
E-mailGet Alerts AIMT Hot Sheet
Price: $34.49 --0%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 9 | New: 8
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 9 | New: 8
Join SI Premium – FREE
JMP Securities raised its price target on Aimmune Therapeutics (NASDAQ: AIMT) to $45.00 (from $40.00) while maintaining a Market Outperform rating.
Analyst Liisa Bayko said strong efficacy and safety data in the Phase 3 PALISADE trial de-risks shares and bodes well for approval.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- National Beverage (FIZZ) PT Lowered to $31 at UBS
- The Lovesac Co. (LOVE) PT Lowered to $18 at DA Davidson as Guidance Lowered
- UBS Starts Kalyan Jewellers India Ltd (KALYANKJ:IN) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
